Biostem Tech Stock Price, News & Analysis

BioStem Technologies (OTC: BSEM) announced its participation in the Symposium for Advanced Wound Care (SAWC) Spring meeting in Dallas from April 30 – May 4, 2025. The company will co-exhibit with Venture Medical, LLC to showcase their combined offerings: BioStem's placental allografts (AmnioWrap2® and Vendaje AC®) and Venture's OneViewTM platform. The event features scheduled discussions on CAMPS coverage, mobile wound care, and BioREtain® technology. Three scientific posters were accepted for presentation, highlighting clinical outcomes and research on BioStem's proprietary BioREtain® processing method. The company also announced ongoing randomized clinical trials for diabetic foot ulcers and venous leg ulcers, with results expected later in the year.

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived biologics for advanced wound care, has scheduled its first quarter 2025 financial results announcement for May 12, 2025.

The company will host a conference call and webcast at 4:30 PM ET, featuring presentations from CEO Jason Matuszewski and CFO Michael Fortunato. Investors can participate through:

• North America Toll-Free: (800) 715-9871
• International Toll: +1 (646) 307-1963
• Conference ID: 9695874

Interested parties can register for the webcast through the provided link and stay updated by joining BioStem's distribution list and following their social media channels on X and LinkedIn.

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, has announced its participation in the upcoming Centri Capital Conference at Nasdaq headquarters in New York City.

CEO Jason Matuszewski will deliver a presentation on April 22, 2025, at 10:30 AM ET and conduct one-on-one meetings with interested parties. The company's core technology, BioREtain®, is their proprietary processing method focused on maintaining growth factors and preserving tissue structure.

BioStem's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC® products, all processed at their FDA registered and AATB accredited facility in Pompano Beach, Florida. The company maintains quality management systems and standard operating procedures accredited by the American Association of Tissue Banks, following current Good Tissue Practices and Good Manufacturing Processes.

BioStem Technologies (BSEM) reported record preliminary Q4 2024 financial results with net revenue of $102.9 million and full-year revenue of $301.8 million, marking a 1,709% increase from 2023. The company achieved $15.5 million in Q4 GAAP net income ($0.94 per share), its fourth consecutive profitable quarter.

Q4 gross profit reached $99.3 million (97% margin), driven by the nationwide launch of Vendaje AC® and continued demand for AmnioWrap2®. Operating expenses increased to $90.9 million due to expanded headcount and higher service fees.

Recent milestones include initiating three clinical trials for diabetic foot ulcers and venous leg ulcers, securing national CMS pricing for Vendaje AC®, and receiving a patent allowance for placental allografts. The company is currently undergoing SEC review for a planned Nasdaq uplisting.

BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived biologics for advanced wound care, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for April 14, 2025.

The company will host a conference call and webcast at 4:30 PM ET, featuring CEO Jason Matuszewski and CFO Michael Fortunato, who will provide an overview of the quarter. Participants can join via North America Toll-Free (800) 715-9871 or International Toll +1 (646) 307-1963 using Conference ID: 9695874.

BioStem Technologies (OTC: BSEM) has requested an extension for filing its 2024 annual report with the OTC. The delay is attributed to an ongoing SEC review process of the company's Form 10 registration statement, which could affect financial statements and disclosures.

The company expects to file the annual report by April 15, 2025, the extension period's deadline. Management indicates this review process is a necessary step in their planned Nasdaq uplisting. A webcast covering Q4 and year-end 2024 results will be announced following the completion of the SEC review.

BioStem Technologies (OTC: BSEM) has received Notice of Allowance from the USPTO for two patent applications, strengthening its intellectual property portfolio in advanced wound care technology. The company currently holds 43 issued patents and has 26 pending applications.

The first patent (No. 18/593,225) covers novel micronized human placental compositions for wound care, specifically designed for wound packing, irregular surfaces, weeping wounds, and dental/oral applications. The second patent (No. 18/290,914) pertains to sterile human placental allograft compositions manufactured with the BioRetain® process, aimed at treating conditions like diabetic foot ulcers and dental wounds.

BioStem Technologies (OTC: BSEM) announces its participation in the 24th Annual Needham Virtual Healthcare Conference, where CEO Jason Matuszewski will present on April 10, 2025, at 1:30 PM ET. The company will also conduct investor meetings during the conference.

BioStem Technologies specializes in developing and manufacturing placental-derived products for advanced wound care using their proprietary BioREtain® processing method. Their product portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®.

The company maintains AATB accreditation and operates an FDA-registered facility in Pompano Beach, Florida, following Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP). Their processing method focuses on maintaining growth factors and preserving tissue structure for optimal wound care solutions.

BioStem Technologies (OTC: BSEM) has received Institutional Review Board (IRB) approval for a clinical study evaluating its proprietary BioREtain® Amnion Chorion (BR-AC) for treating venous leg ulcers (VLU). The multicenter, randomized, controlled study will enroll at least 60 subjects across 15 U.S. sites, comparing BR-AC to standard care over 12 weeks.

The trial will focus on patients with non-healing, non-infected VLUs with confirmed venous reflux. Subjects will undergo a two-week run-in period with standard wound care before randomization. The primary objective is to assess whether BR-AC increases complete wound closure likelihood compared to standard care alone.

This marks BioStem's third prospective clinical trial across various wound indications. The company's BioREtain® technology is designed to retain tissue's native properties while maintaining the structure and matrix found in fresh perinatal tissue. The VLU market is growing at over 4% CAGR, affecting up to two million people annually in the United States.